10x Genomics Price to Free Cash Flow Ratio 2018-2024 | TXG

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

PE Ratio P/S Ratio Price/Book Ratio Price-FCF Ratio Net Worth

10x Genomics price to free cash flow ratio from 2018 to 2024. Price to free cash flow ratio can be defined as

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

PE Ratio P/S Ratio Price/Book Ratio Price-FCF Ratio Net Worth

10x Genomics price to free cash flow ratio from 2018 to 2024. Price to free cash flow ratio can be defined as

Related Stocks
Company Name	Market Cap
Tempus AI (TEM)	$8.5B
Inspire Medical Systems (INSP)	$5.3B
Hims & Hers Health (HIMS)	$5.1B
Privia Health (PRVA)	$2.5B
Enovis (ENOV)	$2.5B
IRhythm Technologies (IRTC)	$2.4B
Azenta (AZTA)	$2B
Omnicell (OMCL)	$2B
Clover Health Investments (CLOV)	$1.6B
Schrodinger (SDGR)	$1.4B
Phreesia (PHR)	$1.1B
Butterfly Network (BFLY)	$650M
Standard BioTools (LAB)	$562M
Talkspace (TALK)	$522M
Fulgent Genetics (FLGT)	$520M
Definitive Healthcare (DH)	$483M
Health Catalyst (HCAT)	$459M
TruBridge (TBRG)	$244M
Pulmonx (LUNG)	$237M
SOPHiA GENETICS SA (SOPH)	$214M
American Well (AMWL)	$122M
EUDA Health Holdings (EUDA)	$107M
P3 Health Partners (PIII)	$75M
HeartBeam (BEAT)	$67M
111 (YI)	$53M
CareCloud (CCLD)	$46M
Zepp Health (ZEPP)	$40M
SHL Telemedicine (SHLT)	$40M
Outset Medical (OM)	$39M
Movano (MOVE)	$20M